These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22111970)

  • 1. Novel GLP-1 receptor agonists for diabetes.
    Garber AJ
    Expert Opin Investig Drugs; 2012 Jan; 21(1):45-57. PubMed ID: 22111970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.
    Montanya E
    Expert Opin Pharmacother; 2012 Jul; 13(10):1451-67. PubMed ID: 22725703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
    Spellman CW
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S7-15. PubMed ID: 22267302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Jespersen MJ; Knop FK; Christensen M
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
    Parkes DG; Mace KF; Trautmann ME
    Expert Opin Drug Discov; 2013 Feb; 8(2):219-44. PubMed ID: 23231438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
    Ahrén B; Schmitz O
    Horm Metab Res; 2004; 36(11-12):867-76. PubMed ID: 15655721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2013 Nov; 14(16):2281-96. PubMed ID: 24087882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.